Axon Enterprise, Inc $AXON Stock Position Reduced by Rathbones Group PLC

Rathbones Group PLC decreased its position in Axon Enterprise, Inc (NASDAQ:AXON) by 3.7% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 34,032 shares of the biotechnology company’s stock after selling 1,317 shares during the quarter. Rathbones Group PLC’s holdings in Axon Enterprise were worth $28,176,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Hemington Wealth Management boosted its holdings in Axon Enterprise by 70.8% in the second quarter. Hemington Wealth Management now owns 41 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 17 shares during the period. Whipplewood Advisors LLC raised its holdings in shares of Axon Enterprise by 192.9% during the second quarter. Whipplewood Advisors LLC now owns 41 shares of the biotechnology company’s stock worth $34,000 after purchasing an additional 27 shares during the period. NewSquare Capital LLC lifted its position in shares of Axon Enterprise by 96.2% in the 2nd quarter. NewSquare Capital LLC now owns 51 shares of the biotechnology company’s stock worth $42,000 after buying an additional 25 shares during the last quarter. Washington Trust Advisors Inc. lifted its position in shares of Axon Enterprise by 44.7% in the 2nd quarter. Washington Trust Advisors Inc. now owns 55 shares of the biotechnology company’s stock worth $46,000 after buying an additional 17 shares during the last quarter. Finally, TCTC Holdings LLC boosted its holdings in shares of Axon Enterprise by 75.0% in the 1st quarter. TCTC Holdings LLC now owns 56 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 24 shares during the period. 79.08% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Axon Enterprise

In related news, President Joshua Isner sold 15,919 shares of the business’s stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $746.26, for a total transaction of $11,879,712.94. Following the sale, the president owned 238,379 shares of the company’s stock, valued at $177,892,712.54. The trade was a 6.26% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Patrick W. Smith sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 7th. The stock was sold at an average price of $713.74, for a total value of $7,137,400.00. Following the completion of the sale, the chief executive officer owned 3,033,982 shares of the company’s stock, valued at $2,165,474,312.68. This trade represents a 0.33% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 49,932 shares of company stock worth $36,802,716 in the last three months. Insiders own 4.40% of the company’s stock.

Axon Enterprise Trading Up 2.6%

Shares of AXON stock opened at $602.51 on Monday. Axon Enterprise, Inc has a 1 year low of $469.24 and a 1 year high of $885.91. The firm has a market capitalization of $47.54 billion, a PE ratio of 148.77, a price-to-earnings-growth ratio of 29.49 and a beta of 1.45. The stock has a fifty day moving average of $719.61 and a two-hundred day moving average of $737.16. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.71 and a current ratio of 2.95.

Axon Enterprise (NASDAQ:AXON) last issued its quarterly earnings data on Tuesday, November 4th. The biotechnology company reported $1.17 earnings per share for the quarter, missing analysts’ consensus estimates of $1.63 by ($0.46). The company had revenue of $710.64 million for the quarter, compared to the consensus estimate of $704.83 million. Axon Enterprise had a net margin of 13.64% and a return on equity of 6.80%. Axon Enterprise’s revenue for the quarter was up 30.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.45 earnings per share. Axon Enterprise has set its Q4 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, research analysts expect that Axon Enterprise, Inc will post 5.8 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the stock. Northland Securities set a $800.00 price objective on shares of Axon Enterprise in a research note on Tuesday, August 5th. JPMorgan Chase & Co. increased their price target on Axon Enterprise from $730.00 to $850.00 and gave the stock an “overweight” rating in a research report on Thursday, July 17th. The Goldman Sachs Group cut their price target on Axon Enterprise from $940.00 to $800.00 and set a “buy” rating on the stock in a report on Wednesday, November 5th. UBS Group lowered their price objective on Axon Enterprise from $840.00 to $610.00 and set a “neutral” rating for the company in a research note on Wednesday, November 5th. Finally, Zacks Research lowered Axon Enterprise from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 2nd. Fifteen equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, Axon Enterprise has an average rating of “Moderate Buy” and a consensus price target of $810.71.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.